These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36396775)

  • 21. The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer.
    Zhang A; Wang X; Fan C; Mao X
    Front Endocrinol (Lausanne); 2021; 12():687244. PubMed ID: 34803903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation oncotype DX
    Lashen A; Toss MS; Fadhil W; Oni G; Madhusudan S; Rakha E
    Histopathology; 2023 Apr; 82(5):755-766. PubMed ID: 36631400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.
    Yanai A; Inoue N; Yagi T; Nishimukai A; Miyagawa Y; Murase K; Imamura M; Enomoto Y; Takatsuka Y; Watanabe T; Hirota S; Sasa M; Katagiri T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):197-203. PubMed ID: 25600244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of PI3K/Akt signaling and hormone resistance in breast cancer.
    Tokunaga E; Kimura Y; Mashino K; Oki E; Kataoka A; Ohno S; Morita M; Kakeji Y; Baba H; Maehara Y
    Breast Cancer; 2006; 13(2):137-44. PubMed ID: 16755107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.
    Ueda S; Tsuda H; Saeki T; Omata J; Osaki A; Shigekawa T; Ishida J; Tamura K; Abe Y; Moriya T; Yamamoto J
    Breast Cancer; 2011 Oct; 18(4):299-308. PubMed ID: 20617404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
    Generali D; Fox SB; Brizzi MP; Allevi G; Bonardi S; Aguggini S; Milani M; Bersiga A; Campo L; Dionisio R; Vergoni F; Giardini R; Dogliotti L; Bottini A; Harris AL; Berruti A
    Clin Cancer Res; 2008 May; 14(9):2673-80. PubMed ID: 18451231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unchartered waters: Significance of fall in Ki67 index after short-term preoperative endocrine therapy in early breast cancers.
    Louis DM; Nair LM; Vijaykumar DK; Vallonthaiel AG; Yesodharan J; Bhaskaran R; Narmadha MP
    Breast Dis; 2023; 42(1):27-36. PubMed ID: 36872762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression levels of SF3B3 correlate with prognosis and endocrine resistance in estrogen receptor-positive breast cancer.
    Gökmen-Polar Y; Neelamraju Y; Goswami CP; Gu X; Nallamothu G; Janga SC; Badve S
    Mod Pathol; 2015 May; 28(5):677-85. PubMed ID: 25431237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ki-67, 21-Gene Recurrence Score, Endocrine Resistance, and Survival in Patients With Breast Cancer.
    Lee J; Lee YJ; Bae SJ; Baek SH; Kook Y; Cha YJ; Lee JW; Son BH; Ahn SH; Lee HJ; Gong G; Jeong J; Lee SB; Ahn SG
    JAMA Netw Open; 2023 Aug; 6(8):e2330961. PubMed ID: 37647069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer.
    Cheng J; Lei L; Xu J; Sun Y; Zhang Y; Wang X; Pan L; Shao Z; Zhang Y; Liu G
    J Nucl Med; 2013 Mar; 54(3):333-40. PubMed ID: 23401605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
    Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
    Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
    Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy.
    Beelen K; Hoefnagel LD; Opdam M; Wesseling J; Sanders J; Vincent AD; van Diest PJ; Linn SC
    Int J Cancer; 2014 Sep; 135(5):1257-63. PubMed ID: 24501006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
    Tajiri W; Ijichi H; Takizawa K; Koi Y; Masuda T; Ueo H; Koga C; Nakamura Y; Taguchi K; Okamoto M; Tokunaga E
    Breast Cancer; 2021 Jan; 28(1):67-74. PubMed ID: 32601800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.
    Creighton CJ; Fu X; Hennessy BT; Casa AJ; Zhang Y; Gonzalez-Angulo AM; Lluch A; Gray JW; Brown PH; Hilsenbeck SG; Osborne CK; Mills GB; Lee AV; Schiff R
    Breast Cancer Res; 2010; 12(3):R40. PubMed ID: 20569503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores.
    Ademuyiwa FO; Thorat MA; Jain RK; Nakshatri H; Badve S
    Mod Pathol; 2010 Feb; 23(2):270-5. PubMed ID: 19946260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
    Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
    Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discordance in 21-gene recurrence scores between paired breast cancer samples is inversely associated with patient age.
    Bernhardt SM; Dasari P; Wrin J; Raymond W; Edwards S; Walsh D; Townsend AR; Price TJ; Ingman WV
    Breast Cancer Res; 2020 Aug; 22(1):90. PubMed ID: 32811558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
    J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
    Fayaz S; Eissa HE; Demian GA
    J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.